Abstract: Synthetic dual-functional ligands targeting specific DNA sequences and histone-modifying enzymes could achieve regulatory control over multi-gene networks in living cells. Unlike the broad array of targeting small molecules for histone deacetylases (HDACs), a few modulators are known for histone acetyltransferases (HATs) playing a central role in transcriptional control. As a novel chemical approach to induce selective HAT-regulated genes, we conjugated a DNA-binding domain (DBD) `I` with N-(4-chloro-3-trifluoromethylphenyl)-2-ethoxy-benzamide (CTB), an artificial HAT activator. Using in vitro enzyme activity assays and microarray studies, here we demonstrate that the distinct functional small molecules could be transformed to have identical bioactivity when conjugated with a targeting DBD. This proof-of-concept synthetic strategy validates the switchable functions of HDAC and HAT in gene regulation and provides a molecular basis for developing versatile bioactive ligands.
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Acetylation of histones is the critical event in transcriptional regulation and gets maintained in an equilibrium state by histone acetyltransferases (HATs) and histone deacetylases (HDACs). 1 Small molecules inhibitors for HDACs can induce global changes in the acetylation profile but in a sequence-independent manner. 2 We previously synthesized a class of sequencespecific small molecules called SAHA-PIPs comprising the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and selective DNA-binding pyrrole-imidazole polyamide (PIP)(s). The biological evaluation showed that SAHA-PIP could induce particular gene networks in mouse and human somatic cells. [3] [4] [5] [6] We showed site-specific inhibition of HDACs and subsequent acetylation of histones as the mechanism behind the distinctive gene-activating ability of SAHA-PIP. 7 Transcriptionally permissive marks are acquired more reliably by activating the epigenetic writers like HATs than by blocking the erasers. 8 The CREB-binding protein (CBP)/p300 family are global transcriptional co-activating HATs that act as the master regulators of gene expression and play essential roles in cell cycle control, differentiation, and apoptosis. 9, 10 Several small molecules are known as acetylation inhibitors. 11 In contrast, only a few HAT activators like Pentadecylidenemalonate, N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-benzamide (CTB), Nemorosone, and TTK21 are known. 12 Considering the essential role of HAT in gene regulation, we chose to confer selectivity to the cell permeable HAT activator CTB by conjugating it with PIP. Recently, SAHA-PIP `I` or SAHA-I (Figure 1 ) was shown to target OCT-3/4 and turn on the HDAC1-repressed core pluripotency genes. 7 The HATs p300/CBP-interacting protein are known to be the critical components of the pluripotency gene network. 13 As an innovative approach to induce HAT-regulated genes, we conjugated the same predesigned DNA sequences in `I` with CTB to synthesize CTB-PIP-I or CTB-I. NH2-CTB or CTB was synthesized by following previously published procedures (Scheme S1). 10 However, NH2-CTB was not suitable for the solid-phase synthesis as the coupling monomer required carboxylic acid. For this reason, HO2C-CTB that can be synthesized by coupling CTB and adipic acid, was devised to optimize the synthesis of CTB-PIP conjugates (Scheme 1) and their purification ( Figure S1 ). Cytotoxicity studies showed that unlike SAHA that kills 50% of cells at 1 µM concentration, CTB and CTB-I had no effect on HDF cells even at 5 µM ( Figure S2 ).
Biological evaluation of the CTB-I was done using microarray with appropriate controls (CTB, SAHA, and SAHA-I) in the conditions optimized 7 and according to preliminary studies. CTB-I remarkably activated an identical cluster of genes like SAHA-I in HDFs ( Figure 1A , CTB-I, and SAHA-I). CTB activated about 12 genes, and SAHA activated a different set of 17 genes ( Figure 1A and B, CTB and SAHA). CTB-I and SAHA-I activated about 26 and 40 genes, respectively, including 24 common genes ( Figure 1B , CTB-I, and SAHA-I). Interestingly, neither CTB nor SAHA shared any genes with each other or with CTB-I and SAHA-I. The scatter plot of the upregulated transcripts in CTB-I-treated HDFs (>2-fold; p < 0.05) produced a strong linear correlation (R 2 = 0.95) with SAHA-I ( Figure 1C ) than that with CTB-treated HDFs (R 2 = 0.37) ( Figure 1D ). CTB-I favored transcriptional activation over repression because 48 genes got upregulated, and 19 genes were downregulated (Table S1 ). Thus, conjugation of PIP markedly altered and boosted the bioactivity of both CTB and SAHA by 2-fold and directed them to identical gene network(s). Analysis of the upstream effectors showed that both SAHA-I and CTB-I activated OCT-3/4 regulated pluripotency genes (Figure 2A) . QRT-PCR analysis validated the expression of the genes identified in Figure 2A , and the endogenous expression of OCT-3/4 was significantly (P < 0.05) induced by more than 50-fold in both SAHA-I and CTB-I treated HDFs. CTB-I also significantly (P< 0.05) induced SOX2, NANOG, LIN28B, EPCAM, and SALL4 and markedly upregulated ZIC3 and DPPA4 ( Figure 2B-I ). This report is the first to show that directed HAT activity trigger the activation of key pluripotency genes and microRNAs like MIR302C 14 ( Figure S3 ). CTB-I and SAHA-I displayed similar gene expression profiles and suggested a common mechanism. To clarify the mode of action, we synthesized a CTB analogue conjugate termed CTBNe-I where the relative position of -CF3 and -Cl in CTB is changed to lack HAT activity according to Kundu and coworkers.
10 (Scheme S1c). A HAT activity study in HDF cells showed that CTB-I retained the HAT activity of CTB as HAT activity got significantly increased in CTB and CTB-I-treated HDFs when compared to that treated with an inactive CTB-Ne-I ( Figure S4 ). SAHA-I showed only a mild increase in HAT activity to suggest the indirect effect caused by HDAC inhibition. This pattern was further substantiated through the enzymatic activity assay study carried out in HeLa nuclear extract where only CTB and CTB-I significantly increased HAT activity when compared to SAHA-I and CTB-Ne-I ( Figure S5 ). Unlike CTB-I and SAHA-I, the inactive analogue CTB-Ne-I did not upregulate the pluripotency genes to validate the need for CTB-mediated HAT activity in gene induction ( Figure S6 ). An HDAC activity assay in cells treated with individual effectors precluded HDAC inhibitory activity of CTB as the possible gene induction mechanism as only SAHA and SAHA-I resulted in HDAC inhibition in cells ( Figure S7 ). In vitro assay carried out with the nuclear extracts from HeLa cells and HDFs further validated this pattern ( Figure  S8 ). Chromatin immunoprecipitation (ChIP)-seq analysis revealed hyperacetylation in the transcribed regions of OCT-3/4 in CTB-I-treated HDFs than in DMSO-treated HDFs ( Figure 2J ). Interestingly, like SAHA-I, CTB-I also resulted in the enrichment in the acetylation level of H3K14 ( Figure S9 ). Also, peaks around the putative promoter region having `I` binding site were identical in CTB-I and SAHA-I-treated HDFs ( Figure 2J (box)).
Recently, high-throughput sequencing studies substantiated the strong binding affinity of PIP 15 , and in accordance with gene expression pattern; SAHA-I had superior binding specificity toward the promoter sequence of human OCT-3/4
7 than the germ cell gene PIWIL1 5 . The in vitro binding association and ChIP-PCR studies verified that the pattern observed in the model oligonucleotide duplex can be extrapolated to the corresponding sequence within the chromatin.
7 CTB-I also triggered hyperacetylation marks in NANOG, SOX2, DPPA4, EPCAM, LIN28, and ZIC3 ( Figure S10 ), however, none had the notable acetylation profile observed in the promoter and transcribed regions of OCT-3/4. CTB-I did not show a marked difference in the acetylation pattern observed in the germ cell genes (PIWIL1 and TDRD1) and the housekeeping gene (GAPDH and HMGB1)( Figure S11 ). The top five significantly enriched pathways verified the CTB-I effect on the expression of the key pluripotency genes (Table S2 , CTB-I treated HDFs). CTB induced an entirely different set of genes associated with liver X receptor (LXR) ( Table S2 , CTB treated HDFs). HDAC1 and p300 bind directly to the overlapping regions of the histone H3 tail and compete with each other. 16 HDAC1 is known to regulate the pluripotency and lineage-specific transcriptional network. 17 The combination of CTB-I and SAHA-I resulted in the expression of OCT-3/4, which has a similar expression profile attained with their individual treatment ( Figure S12 ). Because p300 can acetylate HDAC1 upon activation and attenuate its deacetylase activity, these two synthetic histone-modifiers could be inducing a similar pattern of gene expression. Although the actual mechanism underlying the identical bioactivity is not straightforward, site-specific acetylation triggered by SAHAmediated HDAC inhibition or CTB-mediated HAT activation at a particular key sequence could be causing the activation of OCT-3/4 and its regulated genes.
Considering the importance of HATs in the multi-gene network associated cell biological processes, our study could open new opportunities to modulate HAT-regulated gene(s). CTB-I displayed similar HAT activity pattern in HeLa cells as HDFs to suggest the potential of this strategy in p300 deficient cells. Since the achievement of chemically induced pluripotent stem cells 18 , bioactive ligands aiding cellular reprogramming are in rising demand. Our synthetic strategy could be harnessed to probe the functional interplay between the histone-modifying enzymes in co-ordinating the therapeutically important genes. Tuning of the functional module 19 and expansion of the recognition ability 20 could lead to the construction of robust epigenetic switches with versatile bioactivity.
Experimental Section
Experimental details are shown in the supporting information. ............................................................................................................................................................. mass spectrometer using a positive ionization mode. UV spectra were measured on a Nanodrop ND-1000 spectrophotometer. The biological experiments were only employed on compounds whose purity is at least 95%. 
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Synthesis of CTB unit for P-I conjugates
To a solution of compound 5-nitrosalcylic acid (1 g, 5.46 mmol) in DMF (15 mL) were added K 2 CO 3 (4.52 g, 32.8 mmol) and iodoethane (2.2 ml, 27.5 mmol). The reaction mixture was stirred for 6 h at 50 °C. Evaporation of the solvent gave a yellow residue, which was filtrated with water (20 mL) to produce 1 (955 mg, 3.99 mmol, 73%) as a yellow powder. To a solution of compound 1 (950 mg, 3.99 mmol) in water (15 mL) were added NaOH (1 g, 25 mmol). The reaction mixture was stirred for 15 h at 40 °C. Atfter the filtration, quenching of the solvent by diluted HCl gave a white precipitation, which was filtrated with water (10 mL) to produce 2 (733 mg, 3.47 mmol, 87%) as a white powder. To a solution of compound 5 (580 mg, 1.13 mmol) in water (20 mL) and EtOH (20 mL) were added NaOH (1 g, 25 mmol). The reaction mixture was stirred for 2 h at 90 °C to change brown solution. Atfter the evaporation of EtOH, quenching of the solvent by diluted HCl gave a white precipitation, which was filtrated with water (10 mL) to produce 6 (503 mg, 1.04 mmol, 92%) as a white powder. 
HO 2 C-CTB-Ne
This compound was synthesized as HO 2 C-CTB. under 254 nm) as white powder (13 mg 
CTB-Ne-β-PIIP-γ-PPPP-Dp (CTB-Ne-I.).
Synthesis of the inactive CTB analogue conjugate (CTB-Ne-I) was carried out with the same scheme as 22 
